Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

By Haidong Dong, S. Strome, D. Salomao, H. Tamura, F. Hirano, D. Flies, P. Roche, Jun Lu, G. Zhu, K. Tamada and 3 more. Nature Medicine, 2002

3,182 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/d5fcd7b45dbf0d7f9724b02ebbeb4a8073c40122

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Lieping Chen
2. W. Zou
3. D. Pardoll
4. S. Topalian
5. Janis Taube
6. I. Melero
7. D. Barbie
8. Russell W. Jenkins

In Oncology

1. Lieping Chen
2. W. Zou
3. D. Pardoll
4. S. Topalian
5. Janis Taube
6. D. Barbie
7. Russell W. Jenkins
8. I. Melero

Citations in the corpus

• Immunostimulatory monoclonal antibodies for cancer therapy (2007, background): “B7-H1 expression has been described on various human tumour cell”
• Targeting FTO suppresses cancer stem cell maintenance and immune evasion (2020, neutral): “Evidence is emerging that tumor cells utilize ‘immune checkpoints’ as a major mechanism of immune evasion (Beatty and Gladney, 2015; Dong et al., 2002).”
• Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity (2004, background): “In fact, cell-surface B7-H1 expression is not detectable in most normal tissues, except for a fraction of human tissue macrophage”
• Immunosuppressive networks in the tumour environment and their therapeutic relevance (2005, background): “On the other hand, expression of B7-H1 on human cancers such as ovarian cancer, lung cancer, melanoma, glioblastoma and squamous-cell carcinom”
• CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation (2017, background): “The discovery of immune checkpoint receptors, such as CTLA-4 and PD-1 (5-9), that repress the activity of anti-tumor T cells, led to the development of blocking antibodies directed against these co-inhibitory receptors or their ligands, including ipilimumab (anti-CTLA-4), pembrolizumab (anti-PD-1), ”
• Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity (2003, background): “B7-H1 mRNA is found in a variety of non-lymphoid parenchymal organs, including the heart, placenta, skeletal muscle and lung, and B7-H1 protein has been detected in most human cancers, including ovarian cancer”
• Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. (2005, background): “Tumor B7-H1 is found to promote apoptosis of activated effector T cells ( 12 ) and to decrease susceptibility of tumor cells to lysis by activated Tcells in 4-hour 51Cr release assays”